TLX
Trans-Lux Corp.
NASDAQ · Healthcare · Biotechnology · AU
$9.64
+6.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.8B | 789.8M | 783.2M | 502.5M | 160.1M |
| Cost of Revenue | 815.1M | 370.3M | 273.5M | 188.2M | 65.2M |
| Gross Profit | 1.0B | 419.5M | 509.7M | 314.4M | 94.9M |
| Operating Expenses | |||||
| R&D Expense | 361.9M | 168.3M | 121.0M | 128.8M | 57.9M |
| SG&A Expense | 456.5M | 233.7M | 207.1M | 134.2M | 87.1M |
| General & Admin Expense | 107.1M | 95.0M | 121.7M | 79.3M | 49.1M |
| Selling & Marketing Expense | 92.7M | 138.7M | 85.5M | 54.9M | 38.0M |
| Other Expenses | 131.4M | — | 99.4M | 270.0K | 41.9M |
| Total Operating Expenses | 949.8M | 402.0M | 427.5M | 263.3M | 186.9M |
| Cost and Expenses | 1.8B | 772.3M | 701.1M | 448.5M | 252.0M |
| Operating Income (EBIT) | 70.6M | 17.5M | 82.1M | 15.8M | (91.9M) |
| Non-Operating | |||||
| Interest Income | 14.7M | 5.7M | 10.9M | 671.0K | 1.0K |
| Interest Expense | 31.4M | 36.1M | 21.5M | 8.9M | 406.0K |
| Net Interest Income | (16.7M) | (30.4M) | (10.6M) | (8.3M) | (405.0K) |
| Other Non-Op Income/Expense | 639.9K | (22.6M) | (26.1M) | — | (6.7M) |
| Non-Operating Income (excl Interest) | (375.5K) | (13.4M) | (10.4M) | 35.3M | — |
| EBT (Pre-Tax Income) | 71.3M | (5.2M) | 56.1M | 3.1M | (98.6M) |
| Income Tax Expense | 1.7M | 1.8M | 6.1M | (2.1M) | 5.5M |
| Bottom Line | |||||
| Net Income | 69.6M | (7.0M) | 49.9M | 5.2M | (104.1M) |
| Earnings from Cont. Ops | 69.6M | (7.0M) | 49.9M | 5.2M | (104.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 69.6M | (7.0M) | 49.9M | 5.2M | (104.1M) |
| Per Share | |||||
| Basic EPS | $0.21 | ($0.02) | $0.15 | $0.02 | ($0.33) |
| Diluted EPS | $0.20 | ($0.02) | $0.14 | $0.02 | ($0.33) |
| Revenue Per Share | $5.41 | $2.34 | $2.36 | $1.57 | $0.52 |
| Shares | |||||
| Basic Shares Outstanding | 339.2M | 337.9M | 331.2M | 319.2M | 310.6M |
| Diluted Shares Outstanding | 356.9M | 337.9M | 345.2M | 323.7M | 310.6M |
| Profitability Metrics | |||||
| EBITDA | 122.3M | 52.3M | 100.6M | 23.0M | (92.8M) |
| D&A | 51.3M | 21.4M | 8.0M | 6.7M | 5.4M |
| EBIT | 71.0M | 30.9M | 92.5M | 51.4M | (73.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026